tiprankstipranks
Advertisement
Advertisement
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
PremiumRatingsCaribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
3M ago
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access
Premium
Company Announcements
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access
3M ago
Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year
Premium
The Fly
Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year
3M ago
Caribou Biosciences Reports Increased Losses Amid R&D Focus
PremiumCompany AnnouncementsCaribou Biosciences Reports Increased Losses Amid R&D Focus
6M ago
Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year
Premium
The Fly
Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year
6M ago
FDA appoints Richard Pazdur as Director of CDER
Premium
The Fly
FDA appoints Richard Pazdur as Director of CDER
6M ago
Caribou Biosciences Reports Positive ANTLER Phase 1 Results
PremiumCompany AnnouncementsCaribou Biosciences Reports Positive ANTLER Phase 1 Results
7M ago
Caribou Biosciences announces results from CaMMouflage Phase 1 trial
Premium
The Fly
Caribou Biosciences announces results from CaMMouflage Phase 1 trial
7M ago
Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel
Premium
The Fly
Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100